Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks

Page 2 of 10

9. Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Number of Hedge Fund Holders: 22   

Perceptive Advisors’ Stake: $5.4 million 

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is a biopharmaceutical company dedicated to developing innovative therapies for eye diseases and much more. Robust financial growth and initiatives to enhance eye care and infectious disease prevention make Tarsus Pharmaceuticals a great investment choice. For instance, as per the report of the third quarter of 2024, product sales were $48.1 million compared to $1.7 million for the same period in 2023, driven by more than 41,400 bottles of XDEMVY (lotilaner ophthalmic solution) delivered to patients compared to 1,700 bottles delivered in the prior year period. Secondly, another important milestone the company achieved was the approval for XDEMVY 0.25%. This is for the treatment of demodex blepharitis, a common eyelid condition.

Page 2 of 10